Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

14.96
-0.0450-0.30%
Volume:922.77K
Turnover:13.81M
Market Cap:2.06B
PE:-4.14
High:15.18
Open:15.15
Low:14.76
Close:15.00
52wk High:15.87
52wk Low:4.82
Shares:138.00M
Float Shares:107.00M
Volume Ratio:0.84
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6118
EPS(LYR):-3.0800
ROE:-319.07%
ROA:-29.08%
PB:24.41
PE(LYR):-4.86

Loading ...

Compass Pathways collaborates with Osmind to prepare clinics for psychedelic treatments

Reuters
·
Apr 21

Stock Track | COMPASS Pathways Soars 9.20% in Pre-market After Trump's Executive Order Supports Psychedelic Treatments

Stock Track
·
Apr 21

Stock Track | COMPASS Pathways Soars 9.51% in Overnight Trading After Trump's Executive Order Supports Psychedelic Treatments

Stock Track
·
Apr 21

Psychedelic Stocks Surge After Trump Supports Using Drugs Like LSD for Mental Health

Dow Jones
·
Apr 21

NASD Most Active Issues

Dow Jones
·
Apr 21

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Nuvalent (NUVL)

TIPRANKS
·
Apr 21

H.C. Wainwright Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)

TIPRANKS
·
Apr 21

BUZZ-U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO

Reuters
·
Apr 20

Compass Pathways Price Target Maintained With a $14.00/Share by BTIG

Dow Jones
·
Apr 20

Psychedelic Drug Stocks Surge with Compass Pathways up 37%; Atai Beckley up 28%. Trump Accelerates Psychedelic Research With $50 Million Ibogaine Commitment

Benzinga Earnings
·
Apr 20

Definium Therapeutics Adds 15.3%, Compass Pathways Rises 40%, GH Research Gains 16.4%

THOMSON REUTERS
·
Apr 20

Enveric Biosciences up 150%, U.S.‑Listed Shares of Cybin Rise 2.7%

THOMSON REUTERS
·
Apr 20

BUZZ-U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen

Reuters
·
Apr 20

Top Premarket Gainers

MT Newswires Live
·
Apr 20

Psychedelic Pharmaceutical Companies' Shares Rise Following Executive Order

Dow Jones
·
Apr 20

Psychedelic Drug Developers Rise Premarket After Trump Orders FDA to Expedite Reviews

THOMSON REUTERS
·
Apr 20

Definium Therapeutics up 14.5%, Compass Pathways up 21.5%, GH Research up 18.9%, Enveric Biosciences up 6.6%, U.S.‑Listed Shares of Cybin up 15.5%

THOMSON REUTERS
·
Apr 20

Compass Pathways CEO joins Needham Virtual Psychedelics Forum panel

Reuters
·
Apr 20

BUZZ-Psychedelic drug developers rise after Trump signals regulatory support

Reuters
·
Apr 20

Compass Pathways commends White House order to speed psychedelic treatment access

Reuters
·
Apr 19